2024 Annual Meeting | Industry Therapeutic Update from Eli Lilly and Company: Beyond the Surface: A Case Review Using Amyloid PET in Patients With Suspected Alzheimer’s Disease

��ɫ��

2024 Annual Meeting | Industry Therapeutic Update from Eli Lilly and Company: Beyond the Surface: A Case Review Using Amyloid PET in Patients With Suspected Alzheimer’s Disease

Date Monday 04/15/24

Time 11:45 AM - 12:45 PM MDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Phillip Kuo

Topic(s) General Neurology, Aging, Dementia, and Behavioral Neurology

Learning Objectives An Expert-led clinical discussion on a new therapy for early symptomatic Alzheimer’s disease.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Evaluations

Event Timeline
11:45 AM - 12:45 PM MDT	Speaker	Industry Therapeutic Update from Eli Lilly and Company: Beyond the Surface: A Case Review Using Amyloid PET in Patients With Suspected Alzheimer’s Disease

Faculty Disclosures
Phillip Kuo	No disclosure on file

��ɫ����

��ɫ����

��ɫ��

��ɫ��